Sorrento Therapeutics Inc
Change company Symbol lookup
Select an option...
SRNE Sorrento Therapeutics Inc
TC TuanChe Ltd
ENSG Ensign Group Inc
INO Inovio Pharmaceuticals Inc
WHR Whirlpool Corp
TTOO T2 Biosystems Inc
AAPL Apple Inc
HOKCY Hong Kong and China Gas Co Ltd
NWFFX American Funds New World Fund® Class F-1
CARS Cars.com Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Sorrento Therapeutics, Inc. is a clinical-stage and commercial biopharma company. The Company operates through two segments: Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T), antibody-drug conjugates (ADC), as well as bispecific antibody approaches. Additionally, Sorrento Therapeutics segment also includes Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system to potentially achieve improved efficacy and fewer adverse effects than standard parenteral immunotherapy. The Scilex segment is organized around its non-opioid pain management operations.

Closing Price
$9.43
Day's Change
-0.05 (-0.53%)
Bid
--
Ask
--
B/A Size
--
Day's High
9.46
Day's Low
8.64
Volume
(Average)
Volume:
35,168,066

10-day average volume:
34,365,421
35,168,066

SRNE Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Sorrento Therapeutics, Inc Shareholders With Losses Exceeding $250K of Class Action and Lead Plaintiff Deadline: July 27, 2020

11:02 am ET July 27, 2020 (Newsfile) Print

New York, New York--(Newsfile Corp. - July 27, 2020) - Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Sorrento Therapeutics, Inc.("Sorrento" or "the Company") (NASDAQ: SRNE) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Sorrento securities between May 15, 2020 through May 22, 2020, inclusive (the ''Class Period''). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/srne.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Sorrento's initial finding of "100% inhibition" in an in vitro virus infection will not necessarily translate to success or safety in vivo, or in person; (2) the Company's finding was not a "cure" for COVID-19; and (3) as a result of the foregoing, the lawsuit alleges that Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm's site: www.bgandg.com/srne or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Sorrento you have until July 27, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz

212-697-6484 | info@bgandg.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60054

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.